Upstream Bio, Inc. (UPB)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$3.37

-0.05 (-1.46%)

Market Cap: $187.32M

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

50%(4/8)

Avg Surprise

-9.99%

Streak

2 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$-0.73

Range$-0.88 - $-0.52

8 analysts

EPS Revisions

30d

EPS Estimate DriftChange to current

90d ago$-0.71-2.6%

60d ago$-0.70-4.3%

30d ago$-0.70-4.3%

7d ago$-0.73-0.3%

Current$-0.73

Revenue Consensus

$480290

Range$0 - $1M

7 analysts

Period ending Dec 31, 2026

EPS Consensus$-0.66

Range$-1.02 - $0.08

8 analysts

Revenue Consensus

$1M

Range$442920 - $2M

7 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-0.66	$-1.02 - $0.08	-	-	8	-	-
Sep 30, 2026Sep 26EST	-	$-0.73	$-0.88 - $-0.52	-	-	8	4 3 30d	-
Jun 30, 2026Jun 26 Reported Aug 11, 2026Reported Aug 11	$-0.73	$-0.78	$-0.87 - $-0.62	+6.41%	Beat	9	2 5 30d	+1.4%
Mar 31, 2026Mar 26 Reported May 13, 2026Reported May 13	$-0.75	$-0.75	$-0.89 - $-0.64	+0.00%	Beat	8	1 2 30d	-47.1%
Dec 31, 2025Dec 25 Reported Mar 26, 2026Reported Mar 26	$-0.78	$-0.70	$-0.70 - $-0.65	-11.43%	Miss	3	1 0 30d	-90.2%
Sep 30, 2025Sep 25 Reported Nov 5, 2025Reported Nov 5	$-0.63	$-0.78	$-0.85 - $-0.67	+19.23%	Beat	5	1 2 30d	+90.9%
Jun 30, 2025Jun 25 Reported Aug 6, 2025Reported Aug 6	$-0.74	$-0.61	-	-21.31%	Miss	-	-	+93.4%
Mar 31, 2025Mar 25 Reported May 6, 2025Reported May 6	$-0.51	$-0.48	$-0.59 - $-0.40	-6.25%	Miss	4	No revisions (30d)	-
Dec 31, 2024Dec 24 Reported Mar 13, 2025Reported Mar 13	$-0.41	$-0.54	$-0.77 - $-0.39	+24.12%	Beat	4	No revisions (30d)	-
Sep 30, 2024Sep 24 Reported Oct 11, 2024Reported Oct 11	$-6.96	$-3.65	-	-90.68%	Miss	-	-	-
Jun 30, 2024Jun 24 Reported Aug 28, 2024Reported Aug 28	$-11.18	$0.00	-	N/A	Miss	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.17	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-5481.00%
ROE	-46.10%	ROIC	N/A
Financial Health
Debt/Equity	0.00x	Interest Coverage	N/A
Current Ratio	27.99x	Quick Ratio	27.99x
Trading Statistics
Beta	1.39	Avg Volume	914.41K
52-Week High	$33.68	52-Week Low	$3.29

Technical Indicators Dashboard

Moving Averages

SMA 10$4.29

SMA 20$4.78

SMA 50$5.84

SMA 200$10.69

EMA 10$4.15

EMA 20$4.65

EMA 50$5.54

EMA 200$9.40

MACD

Line: -0.61Signal: -0.48Hist: -0.13

ADX

ADX: 44.5+DI: 7.6-DI: 40.6

Aroon & PSAR

Aroon Up8.0

Aroon Down100.0

PSAR$4.43

Bollinger Bands

Upper Band$6.11

Lower Band$3.44

%B Position5593%(Upper)

Band Width-0.03

RSI (14-Day)

Oversold

17.6

Momentum Oscillators

Stoch %K3.8

Stoch %D6.2

Williams %R-96.1

ROC (10d)-33.1%

Momentum-1.67

CCI (20d)-186.0

MFI (14d)14.2

Volatility Measures

ATR (14d)$0.35(10.4%)

StdDev (20d)0.67

Hist Vol73.2%(High)

Volume Flow

VWAP$3.40

OBV-17.9M

AD Line-10.0M

CMF (20d)-0.052

Volume Metrics

Avg Vol (20d)954.3K

Vol Ratio1.3x

VWMA (20d)$4.59

Pivot Points

R3$3.89

R2$3.75

R1$3.58

Pivot Point$3.44

S1$3.27

S2$3.13

S3$2.96

Advanced Oscillators

TSI-51.65

Ultimate Osc33.5

KST-272.46

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$773,000	$1.03M	$668,000	$683,000	$937,000	$566,000	$613,000	$607,000	$510,000	$640,000	$450,000	$621,000
Cost of Revenue	$0	$0	$57,000	$0	$0	$0	$49,000	$0	$0	$0	N/A	$0
Gross Profit	$773,000	$1.03M	$668,000	$683,000	$937,000	$566,000	$613,000	$607,000	$510,000	$640,000	$450,000	$621,000

Operating Expenses	$43.14M	$44.65M	$46.84M	$38.52M	$45.28M	$32.58M	$26.93M	$19.50M	$18.05M	$15.65M	$14.78M	$10.01M
R&D	$36.09M	$36.56M	$40.17M	$32.98M	$37.87M	$25.80M	$21.77M	$15.43M	$14.07M	$11.69M	$11.55M	$7.79M
SG&A	$7.05M	$8.08M	$6.67M	$5.54M	$7.42M	$6.78M	$5.16M	$4.07M	$3.98M	$3.96M	$3.23M	$2.22M
Operating Income	$-42,368,000	$-43,615,000	$-46,167,000	$-37,834,000	$-44,347,000	$-32,013,000	$-26,318,000	$-18,893,000	$-17,540,000	$-15,013,000	$-14,330,000	$-9,386,000

Interest Income	$2.66M	$3.05M	$3.65M	$4.11M	$4.43M	$4.74M	$5.08M	$2.90M	$2.88M	$1.27M	$1.52M	$1.53M
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-39,702,000	$-40,591,000	$-42,459,000	$-33,748,000	$-39,966,000	$-27,270,000	$-21,242,000	$-15,992,000	$-14,678,000	$-10,894,000	$-11,833,000	$-3,102,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0

Net Income	$-39,702,000	$-40,591,000	$-42,459,000	$-33,748,000	$-39,966,000	$-27,270,000	$-21,242,000	$-15,992,000	$-14,678,000	$-10,894,000	$-11,833,000	$-3,102,000

EBITDA	$-42,350,000	$-44,350,000	$-44,684,000	$-37,961,000	$-45,340,000	$-33,705,000	$-25,587,000	$-19,454,000	$-18,684,000	$-12,770,000	$-11,819,000	$-4,629,000
EBIT	$-42,361,000	$-43,645,000	$-46,113,000	$-37,853,000	$-44,397,000	$-32,013,000	$-26,318,000	$-18,896,000	$-17,555,000	$-12,160,000	$-11,833,000	$-4,629,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about UPB

News

UPB - Phase III Respiratory Franchise Expansion And Quarterly Dosing Will Support Long Term Upside Potential

Analysts believe Upstream Bio's verekitug, currently in Phase III for severe asthma and chronic rhinosinusitis with nasal polyps, has significant multi-indication potential in respiratory diseases...

Simply Wall Street•Sep 21, 2026 11:30 PM ET9/21/26•Bullish

Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Rating of "Hold" from Analysts

Upstream Bio, Inc. (NASDAQ:UPB) has received an average rating of "Hold" from analysts, with four buy recommendations, two hold, and one sell...

MarketBeat•Sep 19, 2026 4:47 AM ET9/19/26•Neutral

Houghton Adam Disposes of 700 Upstream Bio Shares at $5.49 Each

Houghton Adam sold 700 shares of Upstream Bio (NASDAQ:UPB) at $5.49 each on September 16, 2026, as recorded under an SEC transaction code S. This sale represented approximately 3.0% of his prior holdings in the company....

Kalkine Media•Sep 18, 2026 2:46 PM ET9/18/26•Neutral

Upstream Bio (UPB) exec offloads shares to cover taxes

Upstream Bio's Chief Business Officer, Adam Houghton, sold 700 shares of common stock at $5.49 per share on September 16...

Stock Titan•Sep 17, 2026 11:30 PM ET9/17/26•Neutral

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

Upstream Bio is advancing its drug verekitug into pivotal Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027. Following productive discussions with the FDA...

GlobeNewswire•Sep 1, 2026 9:54 PM ET9/1/26•Bullish

UPB Valuation and Fair Value

P/E: -1.2x
P/B: 0.7x

See GNG's fair value

UPB Profitability: Margins, ROIC and FCF

Gross margin: 100.0%
Operating margin: -5481.0%
Net margin: 0.0%
ROE: -46.1%
FCF margin: -4321.2%

UPB Competitors

Company	Ticker
Rxsight Inc	RXST
Sharps Technology Inc	STSS
Entrada Therapeutics Inc	TRDA
Sionna Therapeutics, Inc. Common Stock	SION
Eledon Pharmaceuticals Inc	ELDN
Invivyd Inc.	IVVD
Akebia Ther	AKBA
Sutro Biopharma	STRO

Sector: Healthcare

UPB Analyst Ratings

Consensus: Buy
Analysts: 9
Strong Buy: 1
Buy: 6
Hold: 2
Sell: 0
Strong Sell: 0

UPB Bull Case vs Bear Case

Bull case

77.8% of UPB's analyst ratings are Buy or Strong Buy.

Bear case

UPB beat EPS estimates in 37.5% of its last 8 reported quarters.
UPB's quarterly revenue changed -17.5% year over year.

UPB Earnings: Beat Rate and Next Report

Beat rate: 3 of 8 quarters (37.5%)
Average surprise: -10.0%
EPS estimate (fiscal period ending Sep 30, 2026): $-0.73
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 4 up, 3 down

Frequently Asked Questions About UPB

Does UPB pay dividends?

Upstream Bio, Inc. (UPB) does not currently pay a regular dividend.

What is UPB's market cap?

Upstream Bio, Inc. (UPB) has a market capitalization of $187.32M with a current stock price of $3.37.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In